Skip to content

Author

N. Erdmann

We have 2 of 57 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Nirmatrelvir-ritonavir targeting viral persistence in post-COVID-19 condition (long COVID) in the USA (RECOVER-VITAL): a randomised, double-blind, placebo-controlled, phase 2 trial.

BACKGROUND Post-acute sequelae of SARS-CoV-2 infection, more commonly known as long COVID, has emerged as a major health problem. The pathogenesis of long COVID is unknown, but among the leading hypotheses is viral persistence. We aimed to investigate whether the use of the SARS-CoV-2 antiviral nirmatrelvir-ritonavir i...

L. Baden, N. Shah, Sean T. H. Liu et al. · 0 citations
Open access Aug 2026

Emergence of neutralizing RBD antibodies following Omicron infection with limited activity against ancestral SARS-CoV-2

Analysis suggests mAbs generically defined as class 1/4 mAbs may be separated into two classes, like Class 1/4 mAbs, and class 4/1 mAbs that make extensive interactions with the class-4 epitope and limited contacts with the class-1 knob498-596.

M. Piepenbrink, Yao Ma, Simran Panjwani et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.